Trial · NCT02112552
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
NCT02112552, Phase 2, Terminated, Albert Einstein College of Medicine; results first posted 2023-08-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer. Trials, record NCT02112552. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02112552
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
- NCT number
- NCT02112552
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Albert Einstein College of Medicine
- Conditions
Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer, Stage IIIC2 Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
- Interventions
- Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Quality-of-Life Assessment, Laboratory Biomarker Analysis
- First posted
- 2014-04-14
- Last updated
- 2023-08-29
- Results first posted
- 2023-08-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Degree of Tolerability, Estimated by the Proportion of Participants Who Complete 6 Treatment Cycles of IP Carboplatin | Up to 18 weeks | At the end of the study, the proportion of patients who tolerated the therapy will be estimated, along with corresponding 95% confidence intervals. Reasons for discontinuation of therapy will be categorized and summarized by computing frequencies. |
| Secondary | Progression-free Survival | The duration of time from start of treatment to time of progression, or death, whichever happens first, assessed at 1 year | The proportion of responders at one year will be estimated with the Kaplan-Meier method. Surrogate endpoint biomarkers including estrogen, progesterone, and Her2/neu receptor status will be correlated with progression-free survival using the Cox Proportional Hazards model, provided the availability of a sufficient number of events. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Degree of Tolerability, Estimated by the Proportion of Participants Who Complete 6 Treatment Cycles of IP Carboplatin | Up to 18 weeks | Data was not collected/aggregated and therefore not analyzed for Degree of Tolerability | ||
| SECONDARY | Progression-free Survival | The duration of time from start of treatment to time of progression, or death, whichever happens first, assessed at 1 year | Data was not collected/aggregated and therefore not analyzed for Progression Free Survival |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 3 | |
| Overall Study | COMPLETED | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | |
| Overall Study | NOT COMPLETED | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 2 |
Source ClinicalTrials.gov
Adverse events10
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fatigue | General disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Decreased Appetite | Metabolism and nutrition disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Weight Loss | Investigations | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 2 |
| other | Constipation | Gastrointestinal disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| other | Peripheral Neuropathy | Nervous system disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| serious | Hematuria | Renal and urinary disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 1 |
| serious | Neutropenia (febrile) | Blood and lymphatic system disorders | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 0 | 4 |
| Total, other adverse events | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 1 | 4 |
| Total, serious adverse events | Treatment (Paclitaxel, Carboplatin, Radiotherapy) | 2 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA013330 | Cancer Center Support Grant | STEIDL, ULRICH | ALBERT EINSTEIN COLLEGE OF MEDICINE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02112552
GET https://conductscience.org/api/trials/v1/NCT02112552/registered